Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $904.9 million.

  • Iovance Biotherapeutics' Liabilities and Shareholders Equity changed N/A to $904.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 12358.46%. This contributed to the annual value of $910.4 million for FY2024, which is 1666.88% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Liabilities and Shareholders Equity is $904.9 million.
  • Iovance Biotherapeutics' 5-year Liabilities and Shareholders Equity high stood at $966.7 million for Q1 2025, and its period low was $757.3 million during Q2 2023.
  • In the last 3 years, Iovance Biotherapeutics' Liabilities and Shareholders Equity had a median value of $869.8 million in 2024 and averaged $863.8 million.
  • The largest annual percentage gain for Iovance Biotherapeutics' Liabilities and Shareholders Equity in the last 5 years was 1666.88% (2024), contrasted with its biggest fall of 546.37% (2024).
  • Over the past 3 years, Iovance Biotherapeutics' Liabilities and Shareholders Equity (Quarter) stood at $780.4 million in 2023, then grew by 16.67% to $910.4 million in 2024, then decreased by 0.6% to $904.9 million in 2025.
  • Its Liabilities and Shareholders Equity was $904.9 million in Q3 2025, compared to $907.4 million in Q2 2025 and $966.7 million in Q1 2025.